Highest-materiality recent filing
Keros Therapeutics files updated corporate presentation; no specific material facts disclosed
The filing contains no specific new material information beyond a routine corporate presentation update.
Keros Therapeutics Q2 2026 net loss $28.7M; initiates Phase 2 DMD trial for rinvatercept
Net loss of $28.7M in Q2 2026 vs $30.7M in Q2 2025; R&D expenses down to $22.3M from $43.5M.
Keros to receive $20M milestone from Takeda; will distribute 25% to stockholders
$20M milestone triggered by first patient dosed in Phase 3 ELRiSE MDS trial of elritercept vs epoetin alfa for anemia in low-risk MDS.
Keros Therapeutics CFO Keith Regnante resigns; Annita Tanini named interim CFO
CFO Keith Regnante resigns effective Aug 3, 2026, voluntarily with no disagreement over accounting or controls.
Keros appoints Anne Prener to Board of Directors, effective July 1, 2026
Anne Prener, M.D., Ph.D., appointed as Class III director with term expiring at 2029 annual meeting.
Keros Therapeutics announces stockholder votes at 2026 annual meeting
Elected Jean-Jacques Bienaimé and Charles Newton as directors with 10,093,559 and 14,716,598 votes for, respectively.
Keros CEO to present at Goldman Sachs healthcare conference June 8
CEO Jasbir Seehra will participate in fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference.
Keros reports Q1 net loss $23.7M; Takeda plans Phase 3 for elritercept in myelofibrosis
Net loss $23.7M in Q1 2026 vs net income $148.5M in Q1 2025 due to prior-year Takeda license revenue.
Entered agreement with Massachusetts General Hospital for Phase 2 ALS trial within HEALEY ALS MyMatch program.
Keros Therapeutics reports Q4 net loss $23.5M, full-year net income $87.0M
Q4 2025 net loss $23.5M vs. $46.0M loss in Q4 2024; FY 2025 net income $87.0M vs. $187.4M loss in FY 2024.
Keros Therapeutics updates corporate presentation; no material new disclosures in filing
Company furnished a corporate presentation dated March 2026 for investor meetings.
Keros Therapeutics appoints Charles Newton to Board; Carl Gordon resigns effective March 9, 2026
Carl Gordon, Ph.D., resigned from the Board and Compensation Committee, effective March 9, 2026; no disagreement with the Company.
Keros Therapeutics CEO to present at three healthcare conferences in Feb-Mar 2026
Oppenheimer 36th Annual Healthcare Life Sciences Conference on Feb 25, 2026 at 11:20 a.m. ET (corporate presentation).
Keros Therapeutics corporate presentation highlights Phase 2 data and cash runway into 2028
Phase 2 KER-050 in lower-risk MDS: 45% RBC transfusion independence at 24 weeks (ASH Dec 2025).
Keros net loss narrows to $7.3M in Q3; cash runway into H1 2028
Net loss of $7.3M in Q3 2025 versus $53.0M in Q3 2024, driven by Takeda license revenue.
Keros repurchases $181M of stock from ADAR1 & Pontifax at $17.75; plans $194M tender offer
Agreed to repurchase all shares held by ADAR1 (13.3%) and Pontifax (11.8%) at $17.75/share for ~$181M total.
Keros reports KER-065 Phase 1 data: BMD improvements sustained to Day 141
Phase 1 trial in healthy males showed no dose-limiting toxicities or serious adverse events.
Keros CEO to present at Wells Fargo and H.C. Wainwright conferences
CEO Jasbir Seehra will participate in a fireside chat at Wells Fargo Healthcare Conference on Sept 4 at 2:15 p.m. ET.
Keros receives FDA Orphan Drug designation for KER-065 in Duchenne muscular dystrophy
FDA granted Orphan Drug designation for KER-065, a TGF-ß family protein-targeting therapy for DMD.
Keros Q2 net loss narrows to $30.7M; Board plans $375M capital return to stockholders
Net loss of $30.7M in Q2 2025 improved from $45.3M in Q2 2024, driven by Takeda license revenue.
Keros discontinues cibotercept development, prioritizes KER-065; CEO becomes President, COO departs
Discontinuing all internal development of cibotercept (KER-012) after PAH trial termination.
Keros doses first patient in Phase 3 RENEW trial of elritercept; $10M milestone from Takeda
First patient dosed in Phase 3 RENEW trial of elritercept for adults with transfusion-dependent anemia with very low, low, or intermediate risk MDS.
Keros Therapeutics CMO Yung Chyung resigns effective Aug 1, 2025
Chief Medical Officer Yung H. Chyung, M.D. resigned effective August 1, 2025.
Keros Therapeutics concludes strategic review, plans $375M capital return
Board unanimously approved $375M excess capital return to stockholders; structure and terms to be announced.
Keros CEO to speak at Goldman Sachs Healthcare Conference on June 9
CEO Jasbir Seehra to participate in a fireside chat at Goldman Sachs 46th Annual Global Healthcare Conference.
Keros ends PAH program, cuts 45% of staff, expects $17M annual savings
TROPOS trial discontinued after pericardial effusion safety events; all cibotercept PAH development halted.
Keros Therapeutics to Present at Bank of America 2025 Global Healthcare Conference
CEO Jasbir Seehra to participate in fireside chat on May 13, 2025 at 8:00 p.m. Eastern time
Keros Q1 net income $148.5M on Takeda license; cash $720.5M; KER-065 Phase 2 plan Q1 2026
Net income of $148.5M vs net loss of $43.1M YoY; revenue driven by Takeda license agreement.
Keros Therapeutics agrees with Pontifax on director slate & standstill through 2025
Agreement nominates Mary Ann Gray, Ran Nussbaum, and Alpna Seth for election at 2025 annual meeting.
Keros Therapeutics adopts poison pill and launches strategic review including potential sale
Board formed Strategic Committee to evaluate strategic alternatives including sale or business combination.
Keros announces positive Phase 1 results for KER-065; plans Phase 2 in DMD in Q1 2026
KER-065 generally well-tolerated; no serious adverse events or dose-limiting toxicities reported.
Keros Therapeutics amends bylaws to update director nomination procedures, universal proxy rules
Updated advance notice provisions for director nominations, including requirements under Rule 14a-19 and limiting nominees to board seats available.
Keros CEO to present at TD Cowen and Leerink healthcare conferences in March
CEO Jasbir Seehra to present at TD Cowen 45th Annual Healthcare Conference on March 3, 2025 at 9:50 a.m. ET.
Keros Therapeutics Q4 2024 net loss $46.0M; receives $200M Takeda upfront for elritercept
Net loss of $46.0M in Q4 2024 vs $40.2M in Q4 2023; full-year net loss $187.4M.
Keros CEO Jasbir Seehra to present at Guggenheim SMID Cap Biotech Conference on Feb 6
Chair and CEO Jasbir Seehra will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference.
Keros-Takeda license for elritercept effective; $200M upfront payment triggered
Global license agreement with Takeda (TSE:4502/NYSE:TAK) for elritercept became effective Jan 16, 2025.
Keros halts entire Phase 2 PAH trial (all doses, placebo) on pericardial effusion safety
Voluntary halt of all dosing in TROPOS trial, including 1.5 mg/kg and placebo arms, due to new pericardial effusion adverse events.
Keros Therapeutics updates corporate presentation for investor meetings
Presentation dated January 2025 posted on company website and attached as Exhibit 99.1.
Keros halts two high-dose arms of Phase 2 PAH trial after pericardial effusion
Voluntarily halted dosing in 3.0 mg/kg and 4.5 mg/kg cibotercept arms in ongoing TROPOS trial.
Keros reports elritercept Phase 2 data: 134.1 wk median TI in MDS; spleen reductions in MF
55.2% (48/87) of mITT patients achieved overall erythroid response; median TI duration 134.1 weeks in lower-risk MDS.
Keros licenses elritercept to Takeda for $200M upfront; milestones up to $1.1B
Upfront payment of $200M; eligible for up to $370M in development/commercial milestones and $740M in sales milestones.
Keros CEO to present at Piper Sandler and Evercore HealthConx conferences in December
CEO Jasbir Seehra will speak at Piper Sandler 36th Annual Healthcare Conference on Dec 3 at 10:30 a.m. ET.
Keros CEO to present at Guggenheim Healthcare Innovation Conference on Nov 13
CEO Jasbir Seehra will speak at the Guggenheim Healthcare Innovation Conference on November 13, 2024 at 3:30 p.m. ET.
Keros Q3 net loss $53M; cash $530.7M; Phase 2 PAH trial fully enrolled
Net loss of $53.0M in Q3 2024 vs $39.4M in Q3 2023; R&D expenses rose to $49.2M.
Keros Therapeutics appoints Yung H. Chyung as Chief Medical Officer
Dr. Chyung appointed Chief Medical Officer effective November 1, 2024, succeeding Simon Cooper.
Keros completes Phase 2 PAH trial TROPOS enrollment with 113 patients; topline Q2 2025
Completed enrollment of TROPOS Phase 2 trial of cibotercept (KER-012) for pulmonary arterial hypertension.
Keros closes screening for Phase 2 TROPOS trial in PAH; expects topline data in Q2 2025
Phase 2 TROPOS trial of cibotercept (KER-012) for PAH has closed screening.
Keros CEO to present at three healthcare conferences in September 2024
CEO Jasbir Seehra will participate in fireside chats at Morgan Stanley, Wells Fargo, and Cantor conferences.
Keros Therapeutics reports Q2 2024 net loss of $45.3M; cash runway into 2027
Net loss of $45.3M in Q2 2024, up from $37.5M in Q2 2023 due to increased R&D spend.
Keros updates corporate deck; no material facts discernible from truncated exhibit
Keros Therapeutics furnished an updated corporate presentation for investor meetings under Item 7.01.
Carl L. Gordon currently serves as the Chair of the Board and, effective June 30, 2024, will resign from such position and serve as a member of the Board.
the Board appointed Jean-Jacques Bienaimé as Lead Independent Director, effective July 1, 2024.
The Board appointed Christopher Rovaldi to the additional position as the Company’s President, effective July 1, 2024.
On February 29, 2024, Simon Cooper, M.B.B.S., resigned from his position as Chief Medical Officer of Keros Therapeutics, Inc. (the “Company”), effective March 12, 2024, to pursue other opportunities.
Dr. Alpna Seth as a director of the Company, effective on May 1, 2023.
She remains employed by the Company and her title has been changed from Chief Scientific Officer to Senior Vice President of Discovery.
Christopher Rovaldi has been appointed to serve as the Company’s Chief Operating Officer, effective as of February 1, 2022.
Simon Cooper, M.B.B.S., has been appointed to serve as the Company’s Chief Medical Officer, effective as of August 2, 2021
Dr. Cooper is succeeding Claudia Ordonez, M.D., who departed from the Chief Medical Officer position effective July 30, 2021
Max materiality 0.85 · Median 0.60 · Most common event other_material